Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lomitapide - Novelion Therapeutics

Drug Profile

Lomitapide - Novelion Therapeutics

Alternative Names: AEGR-733; BMS-201038; JUXTAPID; Juxtapid; Lojuxta

Latest Information Update: 07 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Amryt Pharma; Novelion Therapeutics; University of Pennsylvania
  • Class Antihyperlipidaemics; Benzamides; Biphenyl compounds; Fluorenes; Piperidines; Small molecules
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type IIa; Hyperlipoproteinaemia type I
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type IIa
  • Registered Hypercholesterolaemia

Most Recent Events

  • 06 Feb 2019 Aegerion Pharmaceuticals enters into a marketing license agreement with Recordati Rare Diseases to commercialise lomitapide for Hyperlipoproteinaemia type IIa in Japan
  • 08 Nov 2018 Novelion Therapeutics plans to discuss proposed development plan for Hyperlipoproteinaemia type I with the US FDA
  • 17 Oct 2018 Launched for Hyperlipoproteinaemia type IIa (Adjunctive treatment) in Italy (PO) before October 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top